whytestocks
4 años hace
Just In: $OSUR OraSure's OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2
BETHLEHEM, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its DNA Genotek subsidiary has received Emergency Use Auth...
Read the whole news OSUR - OraSure's OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2
HokieHead
5 años hace
More nice news this AM. This biotech is turning in to a beast. In since $11 area and dollar costing the whole way up for long term portfolio.
OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries
May 12 2020 - 08:00AM GlobeNewswire Inc.
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench strength, state-of-the-art laboratory, ability to translate data to insights and collective focus on quality and service.
The unified Diversigen operation will continue to offer the science-driven, customized solutions for metagenomics sequencing, bioinformatics, and statistical analysis for the study of the microbiome for which CoreBiome and Diversigen are known. The unification elevates Diversigen as the cornerstone brand for microbiome services in the industry.
The combined organization includes scientific experts representing more than a century of microbiome experience and over 300 articles in respected scientific publications with more than 100,000 citations.
“The new Diversigen brand reflects the combined strength and innovation of these two microbiome service pioneers and positions the OraSure family of companies as an industry leader in this fast-growing industry. Together they will enable us to expand our services as we work to advance global health and bring our customers the tools, services and data-driven insights they need to get reliable, actionable answers to their most critical scientific and healthcare questions,” said Stephen S. Tang, Ph.D., President and Chief Executive Officer, OraSure Technologies, Inc.
All services previously offered under the CoreBiome brand will continue to be available from Diversigen, offering the microbiome market unparalleled choice in sequencing, bioinformatics and analysis services.
The rebrand was implemented after in-depth research, market analysis, and customer conversations. A new Diversigen logo will bring a sharp new visual identity, representing the best of both CoreBiome and Diversigen and characterizes the brand as smart, market-driven, and innovative.
The new Diversigen website is available at diversigen.com.
HokieHead
5 años hace
Article today, big things ahead for Orasure. 2021, possibly billions of units, that’s huge revenues..
OraSure President and CEO Stephen Tang said the company began considering developing a test as COVID-19 began spreading in January and February.
The company plans to develop a SARS-CoV-2 that, like its HIV test, will be suitable for home use and can provide results in under an hour, Tang said. He said the company aims to launch the product in September. Tang said that OraSure can currently manufacture about 13 million tests per year.
He noted, however, that some official plans to safely reopen the economy call for a billion tests per year.
"We're going to have to find a way to massively scale up," he said. "We're looking to design massive manufacturing of this from the start. Our job is to find facilities and manufacturers and partners who can jump in quickly to that manufacturing environment."
He said he anticipated being able to reach "full-scale manufacturing sometime in 2021," with a target of "tens of millions to a billion units per year."
https://www.modernhealthcare.com/technology/rapid-antigen-assays-could-prove-key-addressing-sars-cov-2-testing-limitations
HokieHead
5 años hace
An in-home coronavirus test is being developed in Bethlehem. And the feds are backing it.
Updated Apr 06, 2020; Posted Apr 06, 2020
OraSure Technologies, the Bethlehem-based tech company that gained notoriety years ago with its rapid HIV test, has been awarded a $710,310 federal contract to develop an in-home coronavirus test, the company announced Monday morning.
The contract comes from the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services. It will enable OrasSure to file for special authorization from the FDA allowing the in-home test to debut in the U.S. market.
OraSure is billing the test’s development as a possible breakthrough in the fight against the coronavirus pandemic.
Once its developed and the necessary approvals are obtained, the test would help alleviate the pressure on over-burdened healthcare systems, a news release from OraSure says.
“Healthcare providers, retailers, and online vendors could ship tests directly to an individual’s home, eliminating unnecessary trips to hospitals, doctors’ offices, and testing facilities,” the release says. “This would help maintain social distancing and curb the spread of coronavirus through symptomatic and asymptomatic transmission. Rapid in-home testing could also ease the burden on lab-based testing.”
XenaLives
5 años hace
Security OSUR / OraSure Technologies, Inc. (68554V108)
President and CEO TANG STEPHEN S PHD
ISIN US68554V1089
Industry Surgical and Medical Instruments and Apparatus
Institutional Owners 401
Institutional Shares 58,419,785 - 94.70%
Common Shares Outstanding 61,687,392 shares (as of 2019-03-31)
Institutional Value $ 1,736,356 USD
https://fintel.io/so/us/osur